In clinical trials, FFA has shown efficacy for treatment of seizures associated with Dravet syndrome (DS), Lennox‐Gastaut syndrome (LGS), and CDKL5 deficiency disorder (CDD). This evidence concerns the gene CDKL5 and Dravet syndrome.